Feasibility of MicroRNAs as Biomarkers for Barrett's Esophagus Progression: A Pilot Cross-Sectional, Phase 2 Biomarker Study

[1]  A. Rastogi,et al.  Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett's dysplasia. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  Kenneth K. Wang,et al.  Predictors of Progression in Barrett's Esophagus: Current Knowledge and Future Directions , 2010, The American Journal of Gastroenterology.

[3]  C. Stephan,et al.  Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. , 2010, Clinical chemistry.

[4]  A. Tsykin,et al.  MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma , 2010, The British journal of surgery.

[5]  Shinji Tanaka,et al.  miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. , 2010, Carcinogenesis.

[6]  L. Buscail,et al.  MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. , 2010, Clinical chemistry.

[7]  R. Hruban,et al.  Aberrant MicroRNA-155 Expression Is an Early Event in the Multistep Progression of Pancreatic Adenocarcinoma , 2010, Pancreatology.

[8]  S. Meltzer,et al.  MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. , 2009, Current opinion in pharmacology.

[9]  Israel Steinfeld,et al.  Novel Rank-Based Statistical Methods Reveal MicroRNAs with Differential Expression in Multiple Cancer Types , 2009, PloS one.

[10]  A. Schetter,et al.  MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival , 2009, Clinical Cancer Research.

[11]  Kenneth K Wang,et al.  MicroRNA Expression Signatures in Barrett's Esophagus and Esophageal Adenocarcinoma , 2009, Clinical Cancer Research.

[12]  G. Yousef,et al.  MicroRNAs in clinical oncology: at the crossroads between promises and problems , 2009, Journal of Clinical Pathology.

[13]  Sandra B. Munro,et al.  Detection of Cancer with Serum miRNAs on an Oligonucleotide Microarray , 2009, PloS one.

[14]  R. Souza,et al.  Molecular markers and genetics in cancer development. , 2009, Surgical oncology clinics of North America.

[15]  S. Swisher,et al.  Tumorigenesis and Neoplastic Progression MicroRNA-196 a Is a Potential Marker of Progression during Barrett ’ s Metaplasia-Dysplasia-Invasive Adenocarcinoma Sequence in Esophagus , 2010 .

[16]  F. Sato,et al.  The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. , 2009, Gastroenterology.

[17]  H. Kung,et al.  MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. , 2009, Biochemical and biophysical research communications.

[18]  M. Michael,et al.  MicroRNA-143 and -205 Expression in Neosquamous Esophageal Epithelium Following Argon Plasma Ablation of Barrett’s Esophagus , 2009, Journal of Gastrointestinal Surgery.

[19]  Xiaoman Hong,et al.  Hormonal Regulation of MicroRNA Expression in Periovulatory Mouse Mural Granulosa Cells1 , 2008, Biology of reproduction.

[20]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[21]  S. Jewell,et al.  Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling. , 2008, The Journal of molecular diagnostics : JMD.

[22]  Andrew Feber,et al.  MicroRNA expression profiles of esophageal cancer. , 2008, The Journal of thoracic and cardiovascular surgery.

[23]  P. Sharma,et al.  Low-grade dysplasia in Barrett’s esophagus - an innocent bystander? Pro , 2007, Endoscopy.

[24]  Suna Wang,et al.  Beyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma , 2007, Bioinformatics and biology insights.

[25]  Michael Vieth,et al.  The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. , 2006, Gastroenterology.

[26]  D. Forman,et al.  TP53 and progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population cohort , 2006, Gut.

[27]  R. Sampliner,et al.  Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  L. Lovat,et al.  Cyclin A Immunocytology as a Risk Stratification Tool for Barrett's Esophagus Surveillance , 2006, Clinical Cancer Research.

[29]  P. Marjoram,et al.  The Molecular Signature of Normal Squamous Esophageal Epithelium Identifies the Presence of a Field Effect and Can Discriminate between Patients with Barrett's Esophagus and Patients with Barrett's-Associated Adenocarcinoma , 2005, Cancer Epidemiology Biomarkers & Prevention.

[30]  L. Kearney,et al.  Molecular cytogenetics in haematological malignancy: current technology and future prospects , 2005, Chromosoma.

[31]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[32]  H. Welch,et al.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. , 2005, Journal of the National Cancer Institute.

[33]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[34]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[35]  S. Spechler,et al.  Clinical practice. Barrett's Esophagus. , 2002, The New England journal of medicine.

[36]  Carissa A. Sanchez,et al.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression , 2001, American Journal of Gastroenterology.

[37]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[38]  J K Greenson,et al.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. , 2001, Human pathology.

[39]  Gary Longton,et al.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets , 2000, American Journal of Gastroenterology.

[40]  Patricia L. Blount,et al.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. , 2000 .

[41]  M. Younes,et al.  p53 Protein Accumulation Is a Specific Marker of Malignant Potential in Barrett's Metaplasia , 1997, Digestive Diseases and Sciences.

[42]  L. Arrighi,et al.  [Treatment of breast cancer]. , 1971, Prensa medica argentina.

[43]  L. Christenson,et al.  Quantitative RT-PCR methods for mature microRNA expression analysis. , 2010, Methods in molecular biology.

[44]  G. Gores,et al.  MicroRNAs: key modulators of posttranscriptional gene expression. , 2009, Gastroenterology.

[45]  J. Lieberman.  Micromanaging cancer. , 2009, The New England journal of medicine.